CRISPR Inserts XIST into Extra Chromosome 21 with 20-40% Efficiency
Modified CRISPR achieves 20-40% XIST integration into trisomy 21 stem cells, building on 2013 Nature work and expanding to other aneuploidies while requiring animal validation per primary PNAS source.
Scientists at Beth Israel Deaconess Medical Center and Harvard Medical School used modified CRISPR/Cas9 to integrate the 14 kb XIST gene into the APP locus on the extra chromosome 21 in human stem cells (Lian et al., PNAS, 2026, DOI: 10.1073/pnas.2517953123).
The work improves on Jiang et al. (Nature, 2013, DOI: 10.1038/nature12394) who first showed XIST could initiate silencing of trisomy 21 in iPSCs; integration efficiency for the large construct rose from near-zero to 20-40% via Cas9 modifications while avoiding widespread off-target cuts cited in the primary paper. Original MedicalXpress coverage omitted this direct lineage to the 2013 experiment and underreported applicability to other aneuploidies explicitly noted by the authors.
A 2022 review by Doudna group (Nature Reviews Molecular Cell Biology) on CRISPR delivery advances shows the modified method aligns with patterns that previously scaled HDR efficiency in large payloads; further steps identified include in vivo mouse models of DS to test cognitive rescue and full RNA-seq validation for off-target XIST spreading, gaps not addressed in initial reporting.
AXIOM: Improved XIST integration on chromosome 21 sets stage for scalable chromosome silencing; next proofs in animal DS models will determine if efficiency holds for neural outcomes within 5 years.
Sources (3)
- [1]Primary Source(https://medicalxpress.com/news/2026-04-crispr-bold-silencing-syndrome-extra.html)
- [2]XIST-mediated silencing of trisomy 21(https://www.nature.com/articles/nature12394)
- [3]CRISPR delivery and efficiency advances(https://www.nature.com/articles/s41580-022-00467-8)